BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 18431378)

  • 21. Kidney transplantation and enzyme alpha-galactosidase A therapy in patient with Fabry disease: a case report.
    Dziemianko I; Jezior D; Boratyńska M; Patrzałek D; Kuźniar J; Szyber P; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2925-7. PubMed ID: 18022018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of patients with Fabry disease in Argentina].
    AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
    Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R; Olea T
    Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
    Barbey F; Widmer U; Burnier M; Lidove O
    Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fabry nephropathy and the case for adjunctive renal therapy.
    Wanner C; Breunig F
    J Am Soc Nephrol; 2007 Sep; 18(9):2426-8. PubMed ID: 17699807
    [No Abstract]   [Full Text] [Related]  

  • 26. [Fabry disease--a provocation for pediatrics].
    Hoffmann B; Mayatepek E
    Klin Padiatr; 2006; 218(1):38-40. PubMed ID: 16432775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Management of Fabry disease].
    Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
    Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
    Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
    Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric Fabry disease.
    Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
    Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
    Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
    Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
    Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
    G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous polyarteritis nodosa in a patient with fabry disease.
    Chen HJ; Yang CC; Hsiao CH; Chu CY
    Arch Dermatol; 2008 Jan; 144(1):122-3. PubMed ID: 18209188
    [No Abstract]   [Full Text] [Related]  

  • 33. [Fabry's disease; towards a treatment].
    Linthorst GE; Hollak CE; Bosman DK; Heymans HS; Aerts JM
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2391-5. PubMed ID: 11145093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
    Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.
    Warnock DG; Thomas CP; Vujkovac B; Campbell RC; Charrow J; Laney DA; Jackson LL; Wilcox WR; Wanner C
    J Med Genet; 2015 Dec; 52(12):860-6. PubMed ID: 26490103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.
    Terryn W; Cochat P; Froissart R; Ortiz A; Pirson Y; Poppe B; Serra A; Van Biesen W; Vanholder R; Wanner C
    Nephrol Dial Transplant; 2013 Mar; 28(3):505-17. PubMed ID: 23234755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neurological complications of Fabry-disease].
    Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
    Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
    Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
    Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
    Feriozzi S; Torras J; Cybulla M; Nicholls K; Sunder-Plassmann G; West M;
    Clin J Am Soc Nephrol; 2012 Jan; 7(1):60-9. PubMed ID: 22246281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bilateral femoral head and distal tibial osteonecrosis in a patient with Fabry disease.
    Lien YH; Lai LW
    Am J Orthop (Belle Mead NJ); 2005 Apr; 34(4):192-4. PubMed ID: 15913175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.